| abstract |
A sustained release pharmaceutical dosage unit form for oral administration containing 2 to 12 mg of 5- [4- [2- (N-methyl-N- (2-pyridyl) amino) ethoxy] benzyl] thiazolidin-2,4 -dione, t. j. rosiglitazone, or a pharmaceutically acceptable salt, or solvate thereof, together with a pharmaceutically acceptable carrier, wherein the dosage form provides a plasma concentration of rosiglitazone of at least 50 ng / ml for up to 24 hours. Use of the pharmaceutical composition for the manufacture of a medicament for the treatment of type 2 diabetes mellitus and conditions associated with diabetes mellitus. |